Leukemia Posts Page 2 on Medivizor
Navigation Menu

Leukemia Posts on Medivizor

Can molecular monitoring help treatment and outcomes in patients with chronic myeloid leukemia?

Posted by on Jan 12, 2019 in Leukemia | 0 comments

In a nutshell This study looked at the use of molecular monitoring to assess outcomes in patients with chronic myeloid leukemia. Researchers found that molecular monitoring at 3 and 12 months is beneficial to these patients. Some background Chronic myeloid leukemia (CML) is a cancer of the bone marrow. This leads to an abnormal immune system and...

Read More

Evaluating ibrutinib and obinutuzumab combination for the treatment of chronic lymphocytic leukemia

Posted by on Jan 10, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effectiveness of ibrutinib and obinutuzumab combination in patients with chronic lymphocytic leukemia. This study concluded that this combination is safe and highly effective as a treatment for these patients. Some background Obinutuzumab (Gazyva) and ibrutinib (Imbruvica)...

Read More

Venetoclax-rituximab combination improves survival in patients with unresponsive and relapsed chronic lymphocytic leukemia

Posted by on Jan 5, 2019 in Leukemia | 0 comments

In a nutshell This study looked at the effectiveness of venetoclax-rituximab (Venclexta–Rituxan) in patients with unresponsive or relapsed chronic lymphocytic leukemia (CLL). Researchers found that this treatment improved survival in patients with CLL. Some background Chronic lymphocytic leukemia is a cancer of the bone marrow. This can...

Read More

Using steroid medication to prevent stem cell transplant complications in patients with leukemia

Posted by on Jan 5, 2019 in Leukemia | 0 comments

In a nutshell This study looked at the effects of using steroid medication to prevent complications after stem cell transplant and improve survival in patients with leukemia. Researchers found that low-dose steroids improved outcomes in these patients. Some background Leukemia is a cancer of the blood-forming tissues such as the bone...

Read More

Platelet count to predict treatment response to chemotherapy including decitabine in patients with acute myeloid leukemia

Posted by on Jan 2, 2019 in Leukemia | 0 comments

In a nutshell This study looked at using platelet count to measure response to decitabine (Dacogen) chemotherapy in elderly patients with acute myeloid leukemia (AML). Researchers found that recovered platelet count after treatment is linked with a better response to treatment. Some background Elderly patients often have a poorer response to leukemia...

Read More

Evaluating long-term Intensive chemotherapy combined with ponatinib for ALL treatment

Posted by on Dec 29, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to assess the long-term safety and effectiveness of adding ponatinib (Iclusig) to intensive chemotherapy in the treatment of acute lymphoblastic leukemia. The study found that this treatment is effective on the long-term for these patients. Some background Acute lymphoblastic leukemia (ALL) is a cancer of the bone...

Read More

Lenalidomide and dexamethasone in the treatment of chronic lymphocytic leukemia

Posted by on Dec 22, 2018 in Leukemia | 0 comments

In a nutshell The study looked at the safety and effectiveness of adding dexamethasone (Decadron) to lenalidomide (Revlimid) in previously untreated patients with chronic lymphocytic leukemia (CLL). Researchers concluded that lenalidomide plus dexamethasone is an effective treatment for CLL. Some background Chronic lymphocytic leukemia (CLL) is a...

Read More

Does older age affect outcome in CLL?

Posted by on Dec 22, 2018 in Leukemia | 0 comments

In a nutshell This study wanted to assess the outcomes of chemoimmunotherapy in older patients with chronic lymphocytic leukemia (CLL). Researchers found that chemoimmunotherapy is safe and effective in these patients. Some background Chronic lymphocytic leukemia is a cancer of the bone marrow. It is often associated with older patients and...

Read More